On November 6, 2026, Eli Lilly and Hims & Hers Health announced an agreement that lets patients prescribed by a licensed provider on the Hims & Hers platform buy Lilly's obesity drugs Zepbound (tirzepatide) and Foundayo (orforglipron) at Lilly's standard self-pay prices without leaving the Hims & Hers platform. According to Lilly's release, self-pay pricing starts at $149 a month for Foundayo, Lilly's daily oral GLP-1, and $299 a month for Zepbound. Pharmaceutical Executive reports that until now, Hims patients who wanted Lilly drugs were sent off-site to LillyDirect to complete the purchase.

Why It Matters

**The sexual-health telehealth model is now a pharma distribution channel.** Hims built its customer base on ED, premature ejaculation and hair loss, using cheap acquisition, subscriptions and in-house pharmacy fulfillment. Both of the largest GLP-1 makers are now selling through that same consumer front end, so drug companies have accepted the DTC telehealth funnel as a legitimate route to patients rather than a compounding threat to sue. For men's-health rivals such as Ro, LifeMD and the newer ED-telehealth entrants, the bar has moved: carrying the brand-name drugs on the platform is becoming standard. **Two caveats.** The margin pressure that hit Hims' Q2 results (see the Novo story's August update) does not go away when volumes rise, so the sexual-health franchise remains the profit engine subsidising the weight-loss business. And the no-compounding pledge now covers both Novo and Lilly molecules. That closes off the cheaper route Hims used in 2024–25, which matters if price competition with Amazon One Medical and Ro intensifies again. Hims reports Q3 results on **November 9**, its first chance to show investors what the deal does to volume and gross margin.

The release includes two commitments. First, Lilly says Hims & Hers "has never offered access to compounded copies of Lilly's GLP-1s, and has committed not to do so in the future." Second, both companies say they will protect "independent clinical decision-making," so providers on the platform keep prescribing whatever they judge right for each patient. Lilly USA president Ilya Yuffa framed it as "meeting patients where they already are." Hims CEO Andrew Dudum called it a demonstration of "what innovators can achieve for customers everywhere when we work together."

The deal completes Hims' set of branded GLP-1 partners. Hims signed Novo Nordisk in March for Wegovy and Ozempic (our coverage). GuruFocus, via Yahoo Finance, reported that HIMS shares rose more than 7% in premarket trading on Friday. It also noted the trade-off investors are weighing: branded drugs usually carry lower margins than the compounded versions Hims built its weight-loss business on, so higher patient volumes may not bring comparable profit growth.

Sources

Update — 2026-11-07

Initial entry — story first created.